Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

European Research Council grant · Running

AMBER APOBEC Mutagenesis: a novel Achilles heel of Breast cancer

Coordinator
Erasmus Universitair Medisch Centrum Rotterdam, Netherlands
Runs
1 October 2022 to 30 September 2027
Status
Running
EU funding
€2.5m
Total cost
€2.5m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101055134

What the project is doing

In the project's own words, from its summary on CORDIS.

APOBEC mutagenesis is a cellular mechanism by which genetic alterations are acquired somatically, driven by APOBEC enzyme family members. This mechanism is prominently observed in 15% of primary and 25% of recurrent breast cancer, the most common cause of cancer-related death in middle-aged women. Current evidence suggests APOBEC mutagenesis contributes to all disease stages, i.e. cancer initiation, progression and treatment resistance.

The core idea of the AMBER project is that unravelling the mechanism of APOBEC mutagenesis induction and maintenance will turn this mechanism into breast cancer’s Achilles heel. To prove this, I will answer several challenging research questions: Why is APOBEC mutagenesis operational in breast cancer? How does APOBEC contribute to disease progression? Can we target APOBEC mutagenesis or APOBEC driven tumours specifically?

First, I will reveal epidemiological and molecular evidence for factors inducing APOBEC mutagenesis in breast cancer. This may help to prevent APOBEC mutagenesis from occurring, potentially decreasing breast cancer incidence. Second, using global and single cell genomics, I will secure a link between APOBEC mutagenesis and disease progression, giving leads to delay progression. Third, I will exploit a potential vulnerability of APOBEC driven breast cancer, since I have found that these tumors may depend on a proficient homologous DNA repair (HR) pathway.

When experimentally confirmed, targeting HR may extinguish APOBEC driven disease. Finally, I have observed that APOBEC mutagenesis associates with a profound immune response. I hypothesize that this is due to a new type of neo-epitopes being produced. If proven true, targeting these neo-epitopes provide another effective means to eradicate APOBEC driven tumors. I am confident AMBER will provide the fundamental insights into APOBEC mutagenesis needed to turn it into an Achilles heel which may help to prevent, delay or cure APOBEC driven breast cancer.

Topics

Who is involved

OrganisationCityCountryRole
Erasmus Universitair Medisch Centrum RotterdamRotterdamNetherlandsCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI